Intermittent oral disodium pamidronate in established osteoporosis: A 2 year double-masked placebo-controlled study of efficacy and safety

TY - JOUR

T1 - Intermittent oral disodium pamidronate in established osteoporosis: A 2 year double-masked placebo-controlled study of efficacy and safety

AU - Ryan, P J

AU - Blake, G M

AU - Davie, M

AU - Haddaway, M

AU - Gibson, T

AU - Fogelman, I

PY - 2000

Y1 - 2000

N2 - The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis. Patients on active therapy received disodium pamidronate 300 mg/day (group A) for 4 weeks every 16 weeks, 150 mg/day (group B) for 4 weeks every 8 weeks or placebo (group C). All patients additionally received 500 mg of calcium and 400 IU vitamin D daily. Dual-energy X-ray absorptiometry measurements of the spine, hip, forearm and total body were performed at baseline and 6-monthly for 2 years using a Hologic QDR 1000 device at two sites. Serum osteocalcin and urinary deoxypyridinoline were measured at the above visits and at 3 months. The percentage change (SEM) in spine bone mineral density (BMD) at 2 years based on intention-to-treat analysis was 4.64 (1.01) in group A, 6.10 (0.87) in group B and 1.13 (1.32) in group C. Analysis of variance showed significant increases in group A and B compared with placebo (p

AB - The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis. Patients on active therapy received disodium pamidronate 300 mg/day (group A) for 4 weeks every 16 weeks, 150 mg/day (group B) for 4 weeks every 8 weeks or placebo (group C). All patients additionally received 500 mg of calcium and 400 IU vitamin D daily. Dual-energy X-ray absorptiometry measurements of the spine, hip, forearm and total body were performed at baseline and 6-monthly for 2 years using a Hologic QDR 1000 device at two sites. Serum osteocalcin and urinary deoxypyridinoline were measured at the above visits and at 3 months. The percentage change (SEM) in spine bone mineral density (BMD) at 2 years based on intention-to-treat analysis was 4.64 (1.01) in group A, 6.10 (0.87) in group B and 1.13 (1.32) in group C. Analysis of variance showed significant increases in group A and B compared with placebo (p

UR - http://www.scopus.com/inward/record.url?scp=0034111392&partnerID=8YFLogxK

U2 - 10.1007/PL00004179

DO - 10.1007/PL00004179

M3 - Article

SN - 1433-2965

VL - 11

SP - 171

EP - 176

JO - Osteoporosis International

JF - Osteoporosis International

IS - 2

ER -